Eli Lilly Will Use GeneNews' Osteoarthritis Biomarker Technology | GenomeWeb

NEW YORK (GenomeWeb News) – GeneNews said today that under a new agreement drugmaker Eli Lilly will have select access to its osteoarthritis genomic biomarker program.

Toronto-based GeneNews specializes in using functional genomics for biomarker-based early disease diagnosis.

GeneNews Lead Director and Interim CEO Heiner Dreismann said in statement that the firm's Sentinel Principle technology "can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.